Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute

Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced
treatments to cancer patients

INDIANAPOLIS, Eli Lilly and Company (NYSE: LLY) today announced a three-year extension of its cancer research
collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and
clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to help advance cancer care.
“We are pleased to announce the extension of our collaboration with Dana-Farber Cancer Institute. This collaboration provides an opportunity for
scientists and clinicians at a premier cancer center to bring creative new ideas about the underlying science and how this might drive future clinical
opportunities for multiple Lilly therapeutic candidates,” said Levi Garraway, M.D., Ph.D., senior vice president, global development and medical affairs,
Lilly Oncology. “The extension will provide continued funding for initial testing of several such ideas in the lab and in the clinic, which could eventually
inform new treatment avenues for cancer patients.”
During the first three years of the collaboration, Lilly has been allowed access to expertise within Dana-Farber to further develop multiple pre-clinical
and clinical compounds in Lilly’s pipeline, including new indications, novel combinations, and biomarker strategies. This collaboration has fostered
fresh ideas, strong communication and important feedback in pre-clinical and clinical study design, process and execution.
“Our collaboration with Lilly has provided the opportunity to bridge academia and industry at the early stages of cancer research,” said Barrett Rollins,
M.D., Ph.D., chief scientific officer of Dana-Farber. “Our shared approach has helped speed learning across labs and disease groups, and serves to
enable and accelerate the testing of new hypotheses. This collaboration is important as we consider the potential impact the research may have on
cancer care.”
Under the agreement, Dana-Farber researchers were, and will continue to be, granted permission to conduct independent pre-clinical and clinical
studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. Financial terms of the
agreement were not disclosed.
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for
them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about
Lilly’s commitment to people with cancer, please visit
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.
Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and
management of disease and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us
at and P-LLY
Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) regarding the
potential of cancer research and development at Lilly. This press release reflects Lilly’s current beliefs. However, as with any pharmaceutical product,
there are substantial risks and uncertainties in the process of development and commercialization. Among other risks, there can be no guarantee that
these treatment options will receive regulatory approval, or, if approved, that it will achieve intended benefits or become a commercially successful
product. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United
States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
Refer to:Carole Copeland;; 317-610-6196
SOURCE Eli Lilly and Company

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on

Related post